209 results about "Catecholamine" patented technology

A method and apparatus for delivering corrective therapy through hormone regulation is provided. Inhibition of sympathetic fibers by spinal cord stimulation is used to regulate the levels of hormones such as catecholamines, renin, and calcitonin gene-related peptide. The invention utilizes a closed or open loop feedback system in which physiological parameters such as the concentrations of hormones and sympathetic indicators such as heart rate and urine production are monitored and used to determine the appropriate level of neurostimulation. The site of electrical stimulation includes, but is not limited to, the spinal cord at levels T7–L2 and the associated neural fibers within a region of the T7–L2 dermatomes

A method and apparatus for delivering corrective therapy through hormone regulation is provided. Inhibition of sympathetic fibers by spinal cord stimulation is used to regulate the levels of hormones such as catecholamines, renin, and calcitonin gene-related peptide. The invention utilizes a closed or open loop feedback system in which physiological parameters such as the concentrations of hormones and sympathetic indicators such as heart rate and urine production are monitored and used to determine the appropriate level of neurostimulation. The site of electrical stimulation includes, but is not limited to, the spinal cord at levels T7-L2 and the associated neural fibers within a region of the T7-L2 dermatomes

An implantable medical device is provided for the treatment of a variety of disorders. The implantable medical device can be a neurostimulator having a stimulation lead and electrode(s) configured to be implanted on or near neural tissue in communication with the adrenal gland. Application of an electrical waveform to the neural tissue can cause the adrenal gland to release catecholamines to treat hypoglycemia. In other embodiments, chemical, magnetic, optical, or mechanical neuromodulation can be used.

Compositions and methods are provided for obtaining stabilized quinol compositions, such as catecholamine drugs (e.g., epinephrine solutions), and also for obtaining stable pharmaceutical formulations that comprise a stabilized quinol composition and a second pharmacologically active component such as a local anesthetic or other active drug ingredient having a reversibly protonated amine group. Stability is achieved through the inclusion of an appropriately selected pH buffer and a thiol agent, based on redox and pH buffering principles including pKa of the buffer and of the reversibly protonated amine group.

The invention discloses a preparation method for a carbon nano tube composite film. The method comprises the following steps: first, allowing a phenolic hydroxyl group, a quinonyl group and other functional groups to be introduced on the surface of a carbon nano tube through oxidation autopolymerization reaction of catecholamine under an alkalescence condition, so as to realize the modification for the surface of the carbon nano tube; then, using water-soluble polymers with amino groups or mercapto groups as raw materials to realize layer-by-layer self-assembly under the action of chemical bonds formed by Schiff base or Michael Addition reaction, thereby obtaining the carbon nano tube composite film. The method has the advantages of mild reaction condition, environmental protection, simplicity and feasibility, and is suitable for industrialized production. The carbon nano tube composite film prepared by the method has the advantages of excellent thermal and chemical stability, ductility, mechanical strength and transparency.

A method of treating neurotransmitter dysfunction in a patient. The method includes the step of administering an amino acid precursor of a catecholamine in a balanced and effective therapeutic range. The catecholamine precursor is preferably L-dopa, but may alternatively be tyrosine, D,L-Phenylalanine or an active isomer thereof, and N-acetyl-L-tyrosine or other amino acid precursor of L-dopa. An amino acid precursor of serotonin in an effective therapeutic range, is also administered. The serotonin precursor is preferably 5-HTP, but may alternatively be tryptophan. At least one cofactor is also preferably administered. Cofactor options include Vitamin B6, Vitamin C, Calcium, Folate, and Cysteine. A method of periodic administration and patient checking is also disclosed.

The present invention relates to novel mammalian DNA-R proteins and genes that encode such proteins. The invention is directed toward the isolation and characterization of mammalian DNA-R proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to rat and human homologues of a mammalian DNA-R gene. Also provided are recombinant expression constructs capable of expressing the mammalian DNA-R genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian catecholamine receptor proteins encoded therein. The invention also provides methods for screening compounds in vitro that are capable of binding to the mammalian DNA-R proteins of the invention, and further characterizing the binding properties of such compounds in comparison with known DNA-R agonists and antagonists. Improved methods of pharmacological screening are provided thereby.

Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.

The invention discloses a method for detecting catecholamine in blood plasma by liquid chromatography tandem mass spectrometry. The method comprises the following steps of preparing a standard product, separating by liquid chromatography, detecting by a mass spectrum, drawing a standard curve, and detecting the catecholamine in the blood plasma. The method has the beneficial effects that the catecholamine is detected by innovatively applying a high-flux liquid chromatography tandem triple quadrupole mass spectrograph; protein is precipitated by acetonitrile, dansyl chloride is used for performing derivative reaction, and the liquid chromatography tandem triple quadrupole mass spectrograph is used for detecting after extraction, so that the pretreatment steps are simple, the interference of a matrix in the blood plasma is effectively removed, and the specificity is good; after the derivatization of dansyl chloride, the detection sensitivity is effectively improved; the high-flux liquid chromatography tandem rod mass spectrograph is used for detecting, three types of catecholamine, including dopamine, epinephrine and norepinephrine, in the blood plasma can be quantitatively and accurately detected; the detection time is short, the flux is high, the detection sensitivity is high, the specificity is good, and the cost is low.

The invention discloses a method for detecting catecholamine and metabolites by using liquid chromatography-tandem mass spectrometry technology. The method can be used for one-time detection of catecholamine and metabolites thereof with high sensitivity and specificity. The method can be used for detecting MN and NMN (indices which are firstly recommended in an association guide), E and NE (effects for auxiliary diagnosis) as well as DA and 3-MT, and the method can be used for carrying out diagnosis of PPGL of various types with very high sensitivity and specificity, wherein the sensitivity and the specificity respectively reach 100% and 97.2%.

The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy.

The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg / kg / min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg / kg / min norepinephrine or less, or to the equivalent of about 0.05 mcg / kg / min norepinephrine or less.

The invention relates to a preparation method of a polymer flooding produced fluid demulsifier. The method comprises the following steps: by using multiramiform tetraphenol ethane catecholamine resin as an initiator, polymerizing with propylene oxide to obtain a demulsifier oleophylic head, and polymerizing the demulsifier oleophylic head with epoxyethane to obtain the multiramiform polyether demulsifier. The demulsifier can be used for efficiently and quickly demulsifying crude oil and especially thick oil. The method solves the problems of low dehydration rate, low dehydration speed and the like in the polymer flooding produced fluid in the prior art, satisfies the harsher requirements for time and dehydration rate of the demulsifier by the offshore platform, and can be used for demulsifying and dehydrating an offshore polymer flooding produced fluid.

The invention discloses a detection method for high throughput liquid chromatogram tandem mass spectrum. The method comprises the following steps: (S1) preparing a sample; (S2) performing derivatization reaction; (S3) pretreating the sample; (S4) separating the liquid chromatogram; and (S5) detecting the tandem mass spectrum. Besides, the invention also discloses a method for detecting four catecholamine metabolites through a high throughput liquid chromatogram tandem mass spectrometry. The detection method provided by the invention is fit for the detection for the catecholamine metabolites in human plasma and has the advantages of simple sample pretreatment, capability of simultaneously detecting four catecholamine metabolites, excellent detection specificity, short time in the whole detection process and high throughput.

The invention discloses a multi-branch structure demulsifier of an aromatic ring core. The demulsifier is prepared by the following processes of alternatively carrying out Michael addition and amidation condensation reaction in a methanol solvent by using two materials of methyl acrylate and a polyamine substance on the basis of the structure of catecholamine resin prepared from aromatic ring phenol, ethanediamine and formaldehyde in a condensation manner; grafting a repetition structure unit of polyamide-polyamidoaminedendrimer (Dendrimer) on the catecholamine resin, and synthesizing a Dendrimer macromolecule of a super-multi-branch aromatic ring core as an initiator; grafting a polyether chain segment by oxyalkylation reaction of a functional group of the Dendrimer macromolecule initiator; regulating and controlling the structure and the ratio of the polyether chain segment, so as to prepare a series of polyether demulsifiers with novel structures.

The present invention relates to a method for preparing a double-sided film containing the step of forming a film in the interface between air and the mixture of a polymer comprising amine group (—NH) and a compound containing phenol or catechol by exposing the mixture on the air. Particularly, the double-sided film of the present invention is a separation membrane that can separate the interface of liquid phase and gas phase and at the same time can be used as a biomaterial such as a haemostatic and also an waterproof agent. When the film is prepared in a moderate condition by using an enzyme, the film can include proteins and cells, resulting in the multi-functional versatility film that can be useful as a biocatalyst. The versatility film of the present invention, thus, is not expensive and the production method thereof is simple and eco-friendly. Therefore, the film of the invention has a high added-value as a novel separation membrane that can replace the conventional separation membrane.

The invention discloses a medicine for treating gynecological diseases. The medicine is prepared by 26 traditional Chinese medicines such as myrrh, frankincense, catecholamine, verdigris, minium, calomel and borneol; and the medicine disclosed by the invention has effects of clearing heat, removing toxicity, promoting blood circulation, removing blood stasis, relieving swelling and pain, diminishing inflammation and relieving itching, can treat various gynecological diseases with high cure rate and rapid efficacy and without toxic and side effects and especially has special effects on pelvic inflammation, endometritis, cervicitis, vaginitis, annexitis and the like. Meanwhile, the medicine disclosed by the invention has the advantages of simple preparation process and easiness in large-scale industrial production.

The invention belongs to the technical field of inorganic materials and analysis and particularly relates to a simple preparation method for formylphenylboronic acid modified magnetic nanoparticles (Fe3O4@PEI-FPBA) and application of the formylphenylboronic acid modified magnetic nanoparticles in selective enrichment of catecholamines in urine. Magnetic microspheres Fe3O4@PEI are synthesized by a one-pot method and then are grafted with phenylboronic acid functional groups through reductive amination reaction so as to form the hybridized magnetic nanoparticles. The magnetic material has the characteristics of simple preparation method, high adsorption capacity, good selectivity and short balancing time; and when the magnetic material is applied to the selective enrichment of a trace amount of catecholamines in the urine, the pretreatment process is simple and rapid and is high in specificity. The material has an excellent application prospect in the enrichment of a 1,2-cis-dihydroxy compound in body fluids.

The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Accordingly, the present invention relates to compounds of formula (Id)whereinR1 is H and R2 is selected from one of the substituents (i) and (ii) below; orR1 is selected from one of the substituents (i) and (ii) below and R2 is H; orR1 and R2 are both represented by substituent (i) below; orR1 and R2 are both represented by substituent (ii) below; orR1 is substituent (i) and R2 is substituent (ii); orR1 is substituent (ii) and R2 is substituent (i);wherein * indicates the attachment point; andwherein the carbon atom at the attachment point on substituent (i) is in the S-configuration;or a pharmaceutically acceptable salt thereof.

The invention discloses a multicolor non-toxic hair dye and a preparation method and dying method thereof. The multicolor non-toxic hair dye is characterized by comprising an A agent and a B agent, wherein the A agent comprises catecholamine or a catecholamine derivative, a thickening agent, a pH-regulating agent, a pigment additive and water; and the B agent comprises an oxidizer, a thickening agent, a pH-regulating agent and water. The catecholamines substances are adopted and oxidized by the oxidizer, so that melanin analogues high in surface adhesion properties are formed, and are coated to the surface of hair in an in situ manner, and the surface color of hair can be changed. Compared with a conventional hair dye, the hair dye disclosed by the invention is free from toxin, and betterin biological safety. The hair dye is high in dying stability, low in cost, simple in preparation technology and favorable for environment prevention, can well meet color diversity requirements, doesnot need to be heated when being used, can be applied to the surface of the hair after the A agent and the B agent are uniformly mixed, and is simple to operate during dying, short in dying time, andwidely applied to various crowds.

The invention relates to the technical field of materials, and provides an amine-rich catecholamine compound and a preparation method thereof. The amine-rich catecholamine compound is prepared by thereaction of a carboxyl-containing plant polyphenol compound and an amine-rich molecule. The invention also provided a catecholamine-based amine-rich surface-modified product, including an alkaline buffer solution and the amine-rich catecholamine compound, and the ratio of the amine-rich catecholamine compound to the alkaline buffer solution is 0.01-100 mg: 1 mL. The amine-rich catecholamine compound is prepared by the reaction of the carboxyl-containing plant polyphenol compound and the amine-rich molecule. A coating formed by the surface-modified product has good wide-spectrum adhesion properties and stable chemical properties under strong acid and strong base conditions, and the surface-modified product can further react with various functional compounds to impart new properties to the coating. A material with the coating on the surface of the material and a method of dip-coating the catecholamine-based amine-rich coating on the surface of the material are also provided.

The invention relates to Chinese medicinal gel for treating gynecological inflammation and a preparation method thereof. The Chinese medicinal gel comprises the following raw material medicaments in part by weight: 270 to 330 parts of sophora flavescens, 250 to 275 parts of Chinese pulsatilla root, 45 to 55 parts of catecholamine, 225 to 275 parts of dandelion, 225 to 275 parts of cortex dictamni, 270 to 330 parts of fructus cnidii, 270 to 330 parts of belvedere fruit, 225 to 275 parts of phellodendron amurense and 225 to 275 parts of sessile stemona root. Each raw material medicament in the Chinese medicinal gel disclosed by the invention has the effects of clearing heat, removing toxicity, dispersing swelling, removing stasis and killing parasites to relieve itching; and the Chinese medicinal gel can be used for treating gynecological diseases such as the vaginitis, the pelvic inflammatory disease, the cervicitis, the cervical erosion and the like.

This invention relates to compositions which enhance a mammal's immune response to a cytokine by administering therapeutic amounts of catalysts for the dismutation of superoxide which include superoxide dismutase enzyme (SOD) and small molecular weight organic ligand mimics of that enzyme (SOD mimetics or SODms), alone or in combination with a cytokine. These compositions may be used in methods for enhancing a mammal's immune response to a virus such as the hepatitis C virus or the human immunodeficiency virus (HIV) or to a tumor thereby inhibiting the proliferation of the tumor. Relatedly, these compositions may be used in methods of treating mammals infected with HIV or mammals suffering from Hepatitis C or AIDS. This invention also relates to methods of enhancing cancer therapy and methods of preventing and treating hypotension in a mammal resulting from the administration of cytokines by the administration of therapeutic amounts of catalysts for the dismutation of superoxide in combination with a cytokine and catecholamine pressor agents. Also provided are pharmaceutical compositions comprising catalysts for the dismutation of superoxide alone or in combination with cytokines and catecholamine pressor agents for use in the above methods.

The invention relates to a method for quantitatively detecting catecholamine and metabolites thereof by liquid chromatography-mass spectrometry. The method mainly comprises the following steps: (1) pretreating a sample; (2) carrying out solid-phase extraction on the pretreated sample solution, and extracting catecholamine and metabolites thereof in the plasma; and (3) specifically detecting each analyte and the internal standard thereof by liquid chromatography-mass spectrometry, and comparing the ratio of the analyte to the internal standard signal with the ratio of a calibration curve to determine the concentration of the analyte. The method can quantitatively detect six catecholamines hormones in a human plasma sample, and the detection result can assist a clinician in diagnosing diseases related to abnormal catecholamines hormone content in an adult.

A composition for local anesthesia which comprises a local anesthetic such as lidocaine hydrochloride as an active ingredient and an agent for sustaining anesthetic action selected from the group consisting of antihistamines such as diphenhydramine hydrochloride or hydroxyzine hydrochloride, and does not substantially contain catecholamines such as epinephrine, which has increased durability of anesthetic action without using catecholamines, and is useful as a safe composition for local anesthesia for performing short-time dental operations such as tooth extraction or oral surgery operations.

The invention discloses a pheochromocytoma metastasis prediction system based on a molecular marker. The system is characterized in that the system comprises a variable input submodule, an analysis module and an output module; the variable input submodule comprises a tumour primary diameter input submodule, a primary tumour part input submodule, a catecholamine secretion type input submodule, a blood vessel invasion state input submodule, an ERBB-2 overexpression state input submodule and an SDHB mutation state input submodule; the analysis module can build a metastasis probability alignment chart and calculate a total risk value based on variables input by the variable input submodule and can calculate a pheochromocytoma metastasis predicted value of a pheochromocytoma patient according to the total risk value; the output module is used for outputting the pheochromocytoma metastasis predicted value of the pheochromocytoma patient. According to the pheochromocytoma metastasis prediction system based on the molecular marker, SDHB germ-line gene mutation and primary tumour ERBB-2 protein high-expression, the diameter and position of a primary tumour, blood vessel invasion and the catecholamine secretion type are combined, and accordingly the pheochromocytoma metastasis prediction system is built and shows more excellent prediction accuracy compared with separately used clinical risk factors.

A sensor for the detection of chemical messengers is described herein. In particular a sensor for the detection of catecholamines, for example dopamine, epinephrine or norepinephrine, is reported. Catecholamines play pivotal roles as neurotransmitters and hormones in the human body. An electrode for detecting a catecholamine comprising a conducting or semi-conducting substrate, and a polymer comprising polyethylenedioxythiophene on said substrate is disclosed. The polymer is doped with a cyclodextrin macrocycle. Suitable cyclodextrin macrocycles include anionic cyclodextrin macrocycles, for example sulfonated β-cyclodextrins (CDs). Also, disclosed in sensor capable of selectively detecting a catecholamine in the presence of ascorbic acid (ascorbate).

The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg / kg / min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg / kg / min norepinephrine or less, or to the equivalent of about 0.05 mcg / kg / min norepinephrine or less.